Recent 8-K filings for ANNX

• May 7, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon Q1 net loss $44.1M ($0.23/sh); cash $225M; GA Ph3 data Q4 2026

  Net loss $44.1M (-$0.23/sh) vs $54.4M (-$0.37/sh) Q1 2025; R&D $35.8M, G&A $10.3M.

• March 30, 2026, 7:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026

  Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Annexon outlines 2026 milestones: GBS MAA filed, GA Phase 3 data H2 2026, oral C1 inhibitor data expected

  Tanruprubart MAA filed in Europe for Guillain-Barré syndrome; U.S. BLA submission with FORWARD data planned in 2026.

• November 14, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Annexon closes $86.25M public offering of common stock and pre-funded warrants

  Priced 25,096,153 shares at $2.60/share and 3,750,000 pre-funded warrants at $2.599 each.

• November 10, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026

  Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.

• August 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Annexon Q2 net loss $49.2M; tanruprubart MAA submission Q1 2026, ARCHER II topline H2 2026

  Net loss $49.2M ($0.34/share) in Q2 2025 vs $29.6M ($0.23) in Q2 2024; R&D $44.2M.

• May 12, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing

  Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.

• March 3, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD

  Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.

• January 13, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Annexon provides 2025 outlook; targets BLA submission for ANX005 in GBS in 1H 2025

  ANX005 for GBS: Phase 3 showed rapid muscle strength improvement vs placebo; BLA submission targeted for 1H 2025.

• January 10, 2025, 6:59 PM ET leadership materiality 0.60 positive item 5.02item 7.01item 9.01 ◈ executive_change

  Annexon appoints commercial executive William 'BJ' Jones to board of directors

  William 'BJ' Jones appointed to Board as Class I director effective Jan 9, 2025, term through 2027 annual meeting.

• December 16, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Annexon positive real-world evidence study of ANX005 in Guillain-Barré Syndrome shows benefit over IVIg/PE

  ANX005 30 mg/kg showed faster improvement in muscle strength vs matched IVIg/PE cohort at week 1 (p<0.0001).

• November 14, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025

  Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.

• October 22, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham

  ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).

• August 12, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Annexon Q2 2024 net loss narrowed to $29.6M; cash $368.7M, runway into H2 2026

  Net loss of $29.6M ($0.23/shr) vs. $35.2M ($0.47/shr) in Q2 2023.

• August 5, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection

  Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).

• June 25, 2024, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Annexon Phase 3 trial of ANX005 meets primary endpoint; GBS patients recover faster

  Primary endpoint at Week 8: 2.41-fold higher likelihood of better health state (p=0.0058).

• June 7, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Annexon prices $125M public offering of common stock and pre-funded warrants

  Priced 13,001,120 shares at $6.25/sh and 7M pre-funded warrants at $6.249/sh; gross proceeds $125M.

• June 4, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Annexon Phase 3 GBS trial meets primary endpoint; ANX005 shows 2.4-fold improvement on GBS-DS at week 8

  Phase 3 trial met primary endpoint: single infusion of ANX005 30 mg/kg achieved 2.4-fold improvement on GBS-DS at week 8 (p=0.0058).

• May 13, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024

  Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.

• May 7, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024

  ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

10 positive 0 negative 16 neutral

source · ANNX on sec.gov